leisure time -WSS

leisure time

author：fashion 2025-10-01 01:51:10 - browse：534

Is Wegovy the future of cardiology? Can Novo Nordisk ever make enough of it? And will there ever be an Apple of pharma?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. In the wake of a massively important clinical trial of Novo Nordisk’s obesity drug Wegovy, our colleague Elaine Chen joins us to explain what we know and don’t know about data that could change the practice of medicine. Then, Mizuho Securities biotech strategist Jared Holz calls in to discuss whether explosive popularity of obesity treatments could help create the first trillion-dollar drug company.

For more on what we cover, here’s the news on the Wegovy study; here’s more on its implications; here’s where you can find episodes of Color Code; and here’s where you can subscribe to the First Opinion Podcast.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： PBM reforms clear House panel

focus

WSS

Gain of function research would be limited under House proposal

FDA's Woodcock to retire early next year

Humana cuts profit projections as Medicare Advantage costs soar

Hospitals look to new technology to keep health care workers safe

Readout Newsletter: The latest at Gilead, Catalent, and the NIH

Poor hospice wound care hurts patients and families

leisure time

leisure time

hotspot

State Dept. review finds Biden bears some blame for Afghanistan failures

Research misconduct: Proposed new rules face resistance

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Humana cuts profit projections as Medicare Advantage costs soar

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

My yearlong odyssey to get my son’s ADHD medication covered

Supreme Court strikes down use of affirmative action

Buoyed by wins on obesity, Novo Nordisk eyes heart disease

Dobbs anniversary: the lost opportunity of abortion as health care

FDA clears AI tool for detecting skin cancer

hotspot

Copay coupons to count toward deductibles, after Biden court move

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

Anthos stroke drug appears safer than common blood thinner

U.K. considers world's first use of meningitis vaccine to address gonorrhea

CRISPR pioneers react to Casgevy, first gene

Readout LOUD podcast: Biotech layoffs, stock slump, 2024 preview

entertainment

Wikipedia

focus

hotspot